Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

AKBA

Akebia Therapeut

NASDAQ

1.435

-0.045

-3.04%

Opening 15:55 07/26 EDT

OPEN

1.520

PREV CLOSE

1.480

HIGH

1.520

LOW

1.410

VOLUME

997.26K

TURNOVER

52 WEEK HIGH

2.480

52 WEEK LOW

0.7801

MARKET CAP

300.77M

P/E (TTM)

-6.4844

Weekly Report: what happened at AKBA last week (0715-0719)?

Weekly Report · 4d ago

Weekly Report: what happened at AKBA last week (0708-0712)?

Weekly Report · 07/15 10:31

Buy Rating Justified by Akebia Therapeutics’ Strengthened Dialysis Negotiations and Positive Commercial Prospects

TipRanks · 07/12 12:15

Akebia regains full rights to kidney disease therapy from CSL

Healthcare Akebia regains full rights to kidney disease therapy from CSL. Vafseo is an oral therapy approved in March to treat anemia due to chronic kidney disease in adults on dialysis. Akebia also hopes to obtain Medicare coverage for the drug.

Seeking Alpha · 07/11 11:53

Akebia Therapeutics Regains Right to Sell Anaemia Drug in U.S.

Dow Jones · 07/11 10:35

Akebia Therapeutics Issues Vafseo Commercial Launch Updates - Quick Facts

NASDAQ · 07/11 10:31

Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan

TipRanks · 07/11 10:30

Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.

Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments of up to $450 million. Akebia has the opportunity to buy down the royalty agreement beginning in 2027. Vafseo WAC pricing of $1,278 for a 30-day supply.

Benzinga · 07/11 10:04

About AKBA

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.